apposters.com
OS Fund
Edit

OS Fund

https://osfund.co
Last activity: 21.11.2021
Active
Invests in categories: DrugPlatformTechnologyProductHealthTechHumanAutomationSoftwareScienceManufacturing
OS Fund invests in entrepreneurs using applied intelligence to commercialize breakthrough discoveries in genomics, synthetic biology, diagnostics, new materials, and data and energy. We seek out platform enabling technologies that accelerate discovery and commercialization. We never invest in a single molecule, model or algorithm. We do hard science investing with technology level risk.

We work with our portfolio companies to develop foundational IP that solves real-world challenges and paves a path for commercialization. We’ve thoughtfully constructed a cross-disciplinary group of companies that are each uniquely contributing to the robust ecosystem they all need to thrive.
News
10
Portfolio
35
Mentions
28
Location: United States, Illinois, Chicago
Employees: 1-10
Founded date: 2014
Investment Type: Venture Capital
Investment Stage: Series A

Portfolio 35

DateNameWebsiteTotal RaisedLocation
21.11.2021Viridosviridos.com$25MUnited Sta...
06.05.2021Aria Pharm...ariapharmaceuticals.com-United Sta...
17.07.2020Vivviv.ai$12.5MUnited Sta...
17.07.2020Health Dat...healthdata.link--
28.04.2020Kenota Hea...kenota.com$9MCanada, On...
19.03.2018twoXARtwoxar.com$13.4M-
29.11.2017Arzedaarzeda.com$98.2M-
13.12.2016Lygoslygos.com$50.5MUnited Sta...
-Exvivoexvivo.com-Canada, On...
-Nanolynanoly.info--
Show more

News 10

DateTitleDescription
22.04.2021Q1 2021 Portfolio Company Updates: $9B increase in NIH funding, Group COVID Testing, Major Partnership Announcements, Fundraising NewsWhile the vaccine roll-out has helped us start our social normalization process, one thing that has remained is the increased attention paid to scientific innovation and acceleration of progress in...
08.01.2021Q4 2020 Portfolio Company Updates: The Biotech Revolution, COVID-19 Vaccines and At-Home Testing, Partnerships and Funding NewsThe seismic shifts of 2020 have sparked an acceleration of innovations which have armed humanity with awareness and ability to create powerful, longstanding positive impact via next generation...
22.10.2020Q3 2020 Portfolio Company Updates: Adaptability and Future Literacy, COVID-19 Testing, Partnership and Funding NewsThere is no doubt that the complex impact of the coronavirus pandemic has challenged us all to reflect on previous strategies, both personally and professionally, and adapt to the rapidly evolving...
-The most incredible technology you’ve never seenThere’s money to be made and lives to be saved with the tiny stuff that’s all around us. Saving the world (or some subset of people in it) is in vogue among the world’s wealthiest. Jeff Bezos...
-OS Fund — Building A Global Biological Immune SystemIncreasing the probability that the human race will thrive. tl:dr After selling my company Braintree (Venmo) to eBay in 2013, I started a venture fund, OS Fund, personally investing $100M. My...
-Scaling AI-Driven Drug Discovery: twoXAR Signs Four Partnerships in a Year and Celebrates Five-year AnniversaryLast year we announced our investment in twoXAR, a company building a next generation drug discovery platform. As twoXAR’s five-year anniversary comes to pass, they have managed to vastly exceed...
-Re-writing Nature’s Recipe Book: How Ginkgo Bioworks is Poised to Upset Almost Every Industry You Can Think OfGinkgo Bioworks, based in Boston, has been in the headlines lately: Ginkgo will “bring biodesign to the masses”. (Fast Company.) Ginkgo will “convince you to love GMOs”. (The Atlantic.)...
-Synthego: The One Stop Shop for Revolutionary Genetic ResearchThis article is part of a series about how OS Fund (OSF) companies are radically redefining our future by rewriting the operating systems of life. Or as we prefer to think about it: Step 1: Put...
-Q2 2020 Portfolio Company Updates: The Fight Against COVID-19, Sustainability Successes, AI for Drug Discovery VictoriesThe second quarter was an unprecedented time in our history; and while much of the world remains in various states of shutdown, our areas of focus at OS Fund have taken center stage. Companies, not...
-A Lesson From SARS-CoV-2: We Need to Build A Real-Time Global Biological Immune SystemA coronavirus has ravaged our planet. Humanity brought to its knees by 29,829 nucleotides of “bad news wrapped in a protein.” In 2014, Jeff Klunzinger and I designed OS Fund to build...

Mentions in press and media 28

DateTitleDescription
30.09.2021DNA-based data storage platform Catalog raises $35MConventional electronic media like flash drives and hard drives require energy consumption to process a vast amount of high-density data and information overload and are vulnerable to security issues due to the limited space for storage. Th...
24.09.2019A-Alpha Bio raises $2.8M for genetically engineered drug discovery platformThe A-Alpha Bio team includes scientist Emily Engelhart, principal scientist David Colby, co-founder and CEO David Younger, co-founder and chief technology officer Randolph Lopez and engineering associate Charles Lin. (A-Alpha Bio Photo) A ...
29.01.2019Houston needs 4 things to emerge as a startup hub, according to this entrepreneurI often think about why Houston's entrepreneurship ecosystem hasn't taken off as much as it should, given the talent pool and the industrial gravity that's concentrated here. I joined Station Houston as one of the very early members in Janu...
21.09.2018Biotech Startup uBiome Raises $83M to Expand World’s Largest Human Microbiome DatabaseuBiome, a microbial genetics company leveraging artificial intelligence to develop wellness products, clinical tests, and therapeutics based on the microbiome, today announced it has raised $83 million in Series C funding. The round was led...
07.08.2018OS Fund to Raise $250M to Back Startups Solving Global ProblemsOS Fund, a Venice, CA-based venture capital firm that invests in entrepreneurs and companies that develop breakthrough discoveries in science to address the most pressing global problems, is raising $250m for OS Fund II. This raise follows ...
19.03.2018TwoXar raises $10 million from SoftBank, Andreessen Horowitz, and OS Fund to grow its AI drug discovery platformDid you miss a session from GamesBeat Summit 2022? All sessions are available to stream now. Learn more. TwoXar, a biopharmaceutical startup that uses artificial intelligence (AI) to identify and develop new medicines, has raised $10 millio...
19.03.2018Bioinformatics startup twoXAR bags $10M in Series AJP Lee, managing director of SoftBank Ventures, will join Andreessen Horowitz general partner Vijay Pande on the twoXAR board of directors. Palo Alto, California-based twoXAR reached this next stage of growth thanks to $3.4 million in seed ...
19.03.2018TwoXar raises $10 million from SoftBank, Andreessen Horowitz, and OS Fund to grow its AI drug discovery platformTwoXar, a biopharmaceutical startup that uses artificial intelligence (AI) to identify and develop new medicines, has raised $10 million in a series A round of funding led by SoftBank’s early-stage venture capital firm, SoftBank Ventures, w...
30.11.2017UPDATE: Arzeda Closes Series A on $15.2m for Plant-Based Computational Protein Production, Led by OS Fund*First published July 27, 2017. Updated November 30 to reflect final close on $15.2 million Seattle-based Arzeda has raised a $15.2 million Series A round to expand the capacity of its synthetic protein and enzyme development operation. The...
30.10.2017Five Startups Set to Disrupt Your Kid’s Halloween CandyIt’s a scary fact for any parent, particularly at bedtime tomorrow: children eat an average of three cups of sugar on Halloween, according to industry estimates. Consensus on nutrition is a rare thing, but the goal of reducing sugar intake ...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In